Boothbay Fund Management’s Cartesian Therapeutics RNAC Stock Holding History

Boothbay Fund Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,491	Closed	-$260K	–	1723
2024 Q4	$260K	Sell	14,491 -27	-0.2%	-$547	0.01%	1120
2024 Q3	$234K	Sell	14,518 -54,022	-79%	-$844K	0.01%	1349
2024 Q2	$1.85M	Buy	+68,540	New	+$1.64M	0.04%	528
2022 Q3	–	Sell	-893	Closed	-$35K	–	2552
2022 Q2	$35K	Buy	+893	New	+$26.5K	﹤0.01%	2123
2022 Q1	–	Sell	-401	Closed	-$39K	–	2483
2021 Q4	$39K	Buy	+401	New	+$43.1K	﹤0.01%	1787
2020 Q1	–	Sell	-5,528	Closed	-$395K	–	1027
2019 Q4	$395K	Buy	+5,528	New	+$267K	0.03%	544
2018 Q2	–	Sell	-1,017	Closed	-$311K	–	873
2018 Q1	$311K	Buy	+1,017	New	+$290K	0.04%	462

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boothbay Fund Management's RNAC Position: Q1 2025 in Review

Boothbay Fund Management sold out of Cartesian Therapeutics (RNAC) in Q1 2025, closing a stake of 14,491 shares — an estimated $260K sold.

Boothbay Fund Management first reported a position in RNAC in Q1 2018 and held it in 7 quarters. The position peaked at $1.85M in Q2 2024. 72 funds tracked by Wall St. Rank hold RNAC as of Q1 2025.

Boothbay Fund Management reported no remaining Cartesian Therapeutics position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 14,491 Cartesian Therapeutics shares in Q1 2025, an estimated $260K.
Boothbay Fund Management first reported a position in Cartesian Therapeutics in Q1 2018 and held it in 7 quarters.
Boothbay Fund Management's Cartesian Therapeutics position peaked at $1.85M in Q2 2024.
72 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.